Pneumagen Company
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Headquarters:
Saint Andrews, Fife, United Kingdom
Total Funding:
£4M
Founded Date:
2016
Employee Number:
1-10
Last Funding Type:
Venture - Series Unknown
Investor Type:
For Profit
Investors Number:
2
Technology:
Anti-infective Drugs
Estimated Revenue:
$1M to $10M
Industry:
PharmTech